Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era

Blood

Volumn 129, Issue 13, 2017, Pages 1763-1767

  Mantha, Simon ^a   Goldman, Debra A ^a   Devlin, Sean M ^a   Lee, Ju Whei ^b   Zannino, Diana ^c,n   Collins, Marnie ^c   Douer, Dan ^a   Iland, Harry J ^d   Litzow, Mark R ^e   Stein, Eytan M ^a   Appelbaum, Frederick R ^f   Larson, Richard A ^g   Stone, Richard ^b   Powell, Bayard L ^h   Geyer, Susan ⁱ   Laumann, Kristina ^e   Rowe, Jacob M ^j   Erba, Harry ^k   Coutre, Steven ^l   Othus, Megan ^f   Park, Jae H ^a   Wiernik, Peter H ^m   Tallman, Martin S ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e MAYO CLINIC   (United States)

^f USA   (United States)

^g SECTION OF HEMATOLOGY ONCOLOGY   (United States)

^h WAKE FOREST BAPTIST HEALTH   (United States)

ⁱ UNIVERSITY OF SOUTH FLORIDA   (United States)

^j RAMBAM MEDICAL CENTER   (Israel)

^k UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m of New York   (United States)

ⁿ MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CREATININE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; PREDNISONE; RETINOIC ACID;

ADULT; AGE; AGED; ARTICLE; BLEEDING; COHORT ANALYSIS; CREATININE CLEARANCE; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTHROMBIN TIME; SENSITIVITY ANALYSIS; THROMBOCYTE COUNT; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMPLICATION; MORTALITY; MULTIVARIATE ANALYSIS; PROGNOSIS;

CLINICAL TRIALS AS TOPIC; COHORT STUDIES; HEMORRHAGE; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; MULTIVARIATE ANALYSIS; PROGNOSIS; TRETINOIN;

EID: 85019137719     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-10-747170     Document Type: Article

References (27)

1. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002;100(13): 4298-4302.
2. Lengfelder E, Haferlach C, Saussele S, et al; German AML Cooperative Group. High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG. Leukemia. 2009;23(12): 2248-2258.
3. Adès L, Guerci A, Raffoux E, et al; European APL Group. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. 2010; 115(9):1690-1696.
4. Sanz MA, Montesinos P, Rayón C, et al; PETHEMA and HOVON Groups. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood. 2010;115(25): 5137-5146.
5. Avvisati G, Lo-Coco F, Paoloni FP, et al; GIMEMA, AIEOP, and EORTC Cooperative Groups. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood. 2011; 117(18):4716-4725.
6. Avvisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans retinoic acid 1 idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) pilot study. Blood. 1996; 88(4):1390-1398.
7. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell’Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood. 1997;90(3):1014-1021.
8. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337(15): 1021-1028.
9. Asou N, Adachi K, Tamura J, et al; Japan Adult Leukemia Study Group. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol. 1998;16(1):78-85.
10. Fenaux P, Chastang C, Chevret S, et al; The European APL Group. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood. 1999;94(4):1192-1200.
11. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood. 2008;111(7): 3395-3402.
12. Watts JM, Tallman MS. Acute promyelocytic leukemia: what is the new standard of care? Blood Rev. 2014;28(5):205-212.
13. Di Bona E, Avvisati G, Castaman G, et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol. 2000;108(4):689-695.
14. Yanada M, Matsushita T, Asou N, et al. Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol. 2007;78(3):213-219.
15. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128-1134.
16. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 2011;118(5): 1248-1254.
17. Rahmé R, Thomas X, Recher C, et al. Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients. Leukemia. 2014;28(12):2422-2424.
18. Paulson K, Serebrin A, Lambert P, et al. Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. Br J Haematol. 2014;166(5):660-666.
19. Dally N, Hoffman R, Haddad N, Sarig G, Rowe JM, Brenner B. Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia - a single center experience in 34 patients. Thromb Res. 2005; 116(2):109-114.
20. Kim DY, Lee JH, Lee JH, et al. Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. Leuk Res. 2011;35(2): 152-158.
21. Chang H, Kuo MC, Shih LY, et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol. 2012;88(4):321-328.
22. Iland H, Bradstock K, Seymour J, et al; Australasian Leukaemia and Lymphoma Group. Results of the APML3 trial incorporating all-transretinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 2012;97(2):227-234.
23. Iland HJ, Bradstock K, Supple SG, et al. All-transretinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120(8):1570-1580; quiz 1752.
24. Iland HJ, Collins M, Bradstock K, et al; Australasian Leukaemia and Lymphoma Group. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015; 2(9):e357-e366.
25. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010;116(19):3751-3757.
26. Coutre SE, Othus M, Powell B, et al. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014; 165(4):497-503.
27. Lo-Coco F, Avvisati G, Vignetti M, et al; Gruppo Italiano Malattie Ematologiche dell’Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369(2):111-121.